LRTM2
Leucine-rich repeat and transmembrane domain-containing protein 2
Also known as: LRTM2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8N967
- Gene
- LRTM2
- Ensembl
- ENSG00000166159
- Chromosome
- 12
- Canonical length
- 370 aa
- Protein class
- Predicted intracellular proteins, Predicted membrane proteins
- Subcellular location
- Cytosol
OverviewNCBI Gene
Predicted to act upstream of or within positive regulation of synapse assembly. Predicted to be located in membrane. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
370 residues, UniProt reviewed canonical sequence.
>Q8N967|LRTM2
1 MLAPGSSPGQ RGRLALQWRQ VSWITCWIAL YAVEALPTCP FSCKCDSRSL EVDCSGLGLT
61 TVPPDVPAAT RTLLLLNNKL SALPSWAFAN LSSLQRLDLS NNFLDRLPRS IFGDLTNLTE
121 LQLRNNSIRT LDRDLLRHSP LLRHLDLSIN GLAQLPPGLF DGLLALRSLS LRSNRLQNLD
181 RLTFEPLANL QLLQVGDNPW ECDCNLREFK HWMEWFSYRG GRLDQLACTL PKELRGKDMR
241 MVPMEMFNYC SQLEDENSSA GLDIPGPPCT KASPEPAKPK PGAEPEPEPS TACPQKQRHR
301 PASVRRAMGT VIIAGVVCGV VCIMMVVAAA YGCIYASLMA KYHRELKKRQ PLMGDPEGEH
361 EDQKQISSVALocalizationUniProt · AlphaFold · HPA
Whether an antibody against LRTM2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.43
- Highest tissue expression
- 9.4 nTPM
Expression across tissuesHPA
Tissue
- cerebral cortex: 9.4 nTPM
- basal ganglia: 7.6 nTPM
- hypothalamus: 3.2 nTPM
- hippocampal formation: 2.3 nTPM
- amygdala: 2.2 nTPM
- retina: 0.9 nTPM
Single-cell type
- brain inhibitory neurons: 17 nCPM
- other brain neurons: 9.8 nCPM
- brain excitatory neurons: 9.4 nCPM
- oligodendrocytes: 0.7 nCPM
- microglia: 0.5 nCPM
- oligodendrocyte progenitor cells: 0.4 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- thalamus: 35 nTPM
- basal ganglia: 34 nTPM
- cerebral cortex: 19 nTPM
- midbrain: 18 nTPM
- hippocampal formation: 17 nTPM
- amygdala: 15 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.43
- gnomAD pLI
- 0.87
- gnomAD missense Z
- 0.49
- DepMap mean gene effect
- 0.1
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LRTM2 as an antibody target. Whether an autoantibody or antibody against LRTM2 could matter depends on whether native LRTM2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LRTM2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label LRTM2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...